Söderström Karin, Nilsson Per, Dalianis Tina, Kjellén Elisabeth, Zackrisson Björn
Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå University, Umeå, Sweden.
Department of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
Radiat Oncol. 2015 May 27;10:117. doi: 10.1186/s13014-015-0422-8.
Elective treatment of lymph nodes in oropharyngeal cancer (OPC) has impact on both regional recurrences (RR) and risk of late side effects. This study was performed to quantify the dose-dependent impact on RR and overall survival (OS) in a prospectively collected cohort of OPC from the ARTSCAN study with emphasis on elective treatment.
ARTSCAN is a previously published prospective, randomized, multicentre study of altered radiotherapy (RT) fractionation in head and neck cancer. In ARTSCAN the elective treatment volume for node positive OPC varied significantly between centres due to local treatment principles. All patients with OPC in complete response after primary treatment were eligible for the present case-control study. Cases were patients with RR during five years follow-up. Patients with no recurrence were eligible as controls. Four controls per case were matched according to T- and N-stage. Mean (D mean) and median (D 50%) dose for the lymph node level (LNL) of RR in the cases and the corresponding LNL in the controls were analysed with conditional logistic regression. OS was estimated with the Kaplan-Meier method and evaluated by multivariate Cox regression analysis.
There was a dose-dependent risk reduction for D 50% in the interval that represented elective treatment (40-50 Gy) (OR = 0.18, p < 0.05) and a trend in the same dose interval for D mean (OR = 0.19, p = 0.07). OS rates at five years were 0.39 (0.24-0.65) for cases and 0.70 (0.62-0.81) for controls (p < 0.001). The Kaplan-Meier and the Cox regression analysis for cases categorised by delivered dose showed an inverse relationship between dose and survival. The cases with RR in a LNL outside planning target volume (PTV) (D mean < 40 Gy) had an OS rate comparable to that of all patients, and those with RR in a LNL in PTVelective (D mean 40-60 Gy) or PTVtumour (D mean >60 Gy) did significantly worse (p < 0.05). The same inverse relationship was also shown for a small subset of patient with known HPV-status, defined by over expression of p16 (p < 0.05).
There was a significant risk reduction for RR of elective treatment. However the OS for patients with RR outside target volumes was not affected, with similar results for patients with HPV-positive OPC. This could be an argument for a prospective randomized study on limited elective target volumes in OPC.
口咽癌(OPC)淋巴结的选择性治疗对区域复发(RR)和晚期副作用风险均有影响。本研究旨在量化在ARTSCAN研究中前瞻性收集的OPC队列中,选择性治疗对RR和总生存期(OS)的剂量依赖性影响,重点关注选择性治疗。
ARTSCAN是一项先前发表的关于头颈部癌放疗(RT)分割方案改变的前瞻性、随机、多中心研究。在ARTSCAN中,由于局部治疗原则,淋巴结阳性OPC的选择性治疗体积在各中心之间差异显著。所有在初始治疗后完全缓解的OPC患者均符合本病例对照研究的条件。病例为在五年随访期间出现RR的患者。无复发的患者作为对照。根据T分期和N分期,每个病例匹配四个对照。采用条件逻辑回归分析病例组RR的淋巴结水平(LNL)以及对照组相应LNL的平均剂量(D平均)和中位剂量(D 50%)。采用Kaplan-Meier方法估计OS,并通过多变量Cox回归分析进行评估。
在代表选择性治疗的剂量区间(40 - 50 Gy)内,D 50%存在剂量依赖性的风险降低(OR = 0.18,p < 0.05),D平均在相同剂量区间也有此趋势(OR = 0.19,p = 0.07)。病例组五年OS率为0.39(0.24 - 0.65),对照组为0.70(0.62 - 0.81)(p < 0.001)。对按给予剂量分类的病例进行Kaplan-Meier分析和Cox回归分析显示,剂量与生存期呈负相关。在计划靶体积(PTV)外的LNL出现RR的病例(D平均 < 40 Gy)的OS率与所有患者相当,而在PTV选择性区域(D平均40 - 60 Gy)或PTV肿瘤区域(D平均 > 60 Gy)出现RR的病例情况明显更差(p < 0.05)。对于一小部分已知HPV状态(由p16过表达定义)的患者,也显示出相同的负相关关系(p < 0.05)。
选择性治疗的RR有显著风险降低。然而,靶体积外出现RR的患者的OS未受影响,HPV阳性OPC患者结果相似。这可能为关于OPC中有限选择性靶体积的前瞻性随机研究提供依据。